Afutuzumab

From Self-sufficiency
Jump to: navigation, search
Afutuzumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD20
Identifiers
CAS Number 949142-50-1
ATC code none
Chemical data
Formula C6512H10060N1712O2020S44
Molar mass 146.1 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Afutuzumab is a monoclonal antibody being developed by Hoffmann-La Roche Inc. for the treatment of lymphoma.[1] It acts as an immunomodulator.[2][3]

References

  1. Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000). 10 (6): 588–96. PMID 19513948. 
  2. Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
  3. International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.